Singh Laboratory
Harjeet Singh, Ph.D.
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Singh Laboratory
Areas of Research
- Acute Myeloid Leukemia
- Adoptive Cell Therapy
- Bone Cancer
- CAR T-cells
- Immunology
- Immunotherapy
- Leukemia
- Lymphoma
- Targeted Therapy
Our translational research laboratory develops next-generation immune cell therapies for hematologic malignancies and solid tumors. Immunotherapy has transformed cancer treatment by harnessing the body’s own immune system and applying insights from its biology to develop powerful, personalized cell-based therapies. Our laboratory combines immune cell engineering, genetic modification and preclinical modeling — including chimeric antigen receptor (CAR) and T cell receptor (TCR) platforms, tumor infiltrating lymphocytes (TILs) and single-cell analyses — to accelerate clinical translation and improve antitumor efficacy.
Our Research Projects
Our current projects include:
- Developing immune cells — T cells, natural killer (NK) cells, T cell receptor (TCR) gdT cells — for immunotherapy
- Designing chimeric antigen receptors (CARs) to achieve a fully competent T cell activation signal for efficient efficacy
- Genetic modification and ex vivo expansion of CAR T cells using viral and non-viral methods (Sleeping Beauty system)
- Developing cytokine co-stimulation by expressing membrane bound form of cytokines on T cells
- Establishing efficacy of genetically modified immune cells in mouse models
- Neo-antigen and TCR identification for solid tumors
- Isolation and characterization of tumor infiltrating lymphocytes (TILs) for various solid tumors
- Single cell analysis of immune cells evaluating motility, killing and gene expression analysis
Singh wins grant to support research advancing targeted and immune‑based therapies for pediatric osteosarcoma
Dr. Singh was recently awarded a $75,000 grant to support his research project, “Click-Activated Antibody–Drug Conjugates to Osteosarcoma is a Rare but Aggressive Bone Potentiate γδ T-Cell Immunotherapy in Osteosarcoma” over the 2026–2027 year.
So, what does that mean? Osteosarcoma is a rare but aggressive bone cancer that mostly affects children and teenagers, and current treatments often fail when the disease spreads or comes back. Dr. Singh research is focused on developing a more precise and safer treatment that delivers powerful cancer killing drugs directly to tumor cells while sparing healthy tissues.
This targeted approach also helps “wake up” the immune system, making cancer cells easier to recognize and attack. By combining this strategy with specialized immune cells that naturally detect stressed cancer cells, we aim to create a more effective and less toxic treatment option for children with high-risk osteosarcoma.
Contact Us
Principal Investigator
Harjeet Singh, Ph.D.
Assistant Professor, Pediatrics Research
Email: HSingh@MDAnderson.org
Phone: 713-745-0642
Office Location
Modular Labs (MOD1.021a)
7777 Knight Road
Houston, TX 77054
Mailing Address
UT MD Anderson
Pediatrics - Research
1515 Holcombe Blvd.
Unit 0853
Houston, TX 77030-4009
Harjeet Singh, Ph.D., Assistant Professor (left), Fiorela Hernandez, M.D., Clinical Assistant Professor (middle), Simon Olivares, B.S., Research Laboratory Coordinator (right)
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.